Par Drugs and Chemicals (NSE:PAR) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:PAR Par Drugs and Chemicals Ltd NSE:PAR
74 GF Score
Price ₹91.00
GF Value ₹207.62
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Par Drugs and Chemicals Research & Development?

Par Drugs and Chemicals NSE:PAR -1.80% 74 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:PAR with a GF Score™ of 74/100 and a GF Value™ of ₹207.62 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Par Drugs and Chemicals's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Par Drugs and Chemicals  (NSE:PAR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Par Drugs and Chemicals Research & Development Related Terms

Par Drugs and Chemicals Research & Development Historical Data

* Premium members only.

The historical data trend for Par Drugs and Chemicals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Par Drugs and Chemicals Research & Development Chart

Par Drugs and Chemicals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Par Drugs and Chemicals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:PAR
74GF Score
Par Drugs and Chemicals Ltd NSE:PAR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Par Drugs and Chemicals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Par Drugs and Chemicals (NSE:PAR) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Par Drugs and Chemicals and its competitors.
Is Par Drugs and Chemicals' Research & Development too high?
Par Drugs and Chemicals' current Research & Development is ₹0 Mil. Overall, Par Drugs and Chemicals has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Par Drugs and Chemicals' Research & Development compare to ZTS?
Par Drugs and Chemicals' Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Par Drugs and Chemicals and its competitors. Par Drugs and Chemicals's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Par Drugs and Chemicals stock overvalued right now?
Based on GuruFocus' analysis, Par Drugs and Chemicals (NSE:PAR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹207.62, compared to a current price of ₹91.00 — trading 56.2% below its estimated fair value. The current Research & Development is ₹0 Mil. Par Drugs and Chemicals' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Par Drugs and Chemicals (NSE:PAR), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Par Drugs and Chemicals (NSE:PAR) Overvalued in 2026?

Based on GuruFocus' analysis, Par Drugs and Chemicals stock appears to be undervalued. The current stock price of ₹91.00 is trading 56.2% below its estimated GF Value™ of ₹207.62. GuruFocus considers Par Drugs and Chemicals to be Significantly Undervalued.

Key valuation signals for NSE:PAR:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹207.62 vs. price of ₹91.00 (56.2% below fair value)
  • GF Score™: 74/100 with 2 warning signs

No single metric tells the full story. See the NSE:PAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Par Drugs and Chemicals Business Description

Address Gotri Vasna Road, 815, Nilamber Triumph, Vadodara, GJ, IND, 390007
Par Drugs and Chemicals Ltd manufactures active Pharmaceutical Ingredients (APIs) and fine chemicals, serving domestic and international markets. Specializing in essential magnesium-based compounds and other specialty chemicals such as Magnesium Hydroxide, Magnesium Trisilicate, Magnesium Carbonate, various grades of Magnesium Oxide, Dried Aluminum Hydroxide Gel, and Sucralfate USP, the Company produces high-quality bulk drugs used in the formulation of finished pharmaceutical products like tablets, capsules, and liquids. Committed to maintaining stringent quality standards and utilizing manufacturing processes, the Company plays a vital role in supplying reliable ingredients that ensure the safety, efficacy, and stability of pharmaceutical formulations internationally.
74GF Score

Get the complete analysis for NSE:PAR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹91.00
Price
₹207.62
GF Value